Trial Profile
Randomized,Open Label,Two-cycle,Crossover,Single Dose Bioequivalency Study of Two Preparations of Ensartinib Capsules in Healthy Chinese Volunteers Under Fasted State and After Meal
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Ensartinib (Primary)
- Indications CNS cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Betta Pharmaceuticals Co Ltd
- 28 May 2018 New trial record